Propanc Biopharma, Inc. - Common Stock (NQ:PPCB)

0.3530 -0.0709 (-16.73%)

Streaming Delayed Price Updated: 3:47 PM EST, Jan 15, 2026 Add to My Watchlist

Price and Volume

Volume	375,530
Open	0.4380
Bid (Size)	0.3423 (300)
Ask (Size)	0.3700 (100)
Prev. Close	0.4239
Today's Range	0.3400 - 0.4380
52wk Range	0.4200 - 1.980
Shares Outstanding	13,364,244
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Today 8:45 EST

The Science, Clinical Promise, & Market Outlook

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Provides Shareholder Update

January 13, 2026

CEO Highlights Significant Progress Achieved & Outlines Ambitious Plans for 2026

From Propanc Biopharma, Inc.

Via GlobeNewswire

Performance

YTD	-38.3%	-38.3%
1 Month	-52.9%	-52.9%
3 Month	-79.6%	-79.6%
6 Month	-80.1%	-80.1%
1 Year	-80.1%	-80.1%

More News

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

December 04, 2025

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

December 22, 2025

From Propanc Biopharma, Inc.

Via GlobeNewswire

What's going on in today's session ↗

December 01, 2025

Via Chartmill

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

December 01, 2025

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

November 17, 2025

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline

November 10, 2025

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

November 04, 2025

From Propanc Biopharma, Inc.

Via GlobeNewswire

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

October 15, 2025

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

October 15, 2025

From Propanc Biopharma, Inc.

Via GlobeNewswire

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

October 07, 2025

From Propanc Biopharma, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Propanc Biopharma, Inc. - Common Stock publicly traded?

Yes, Propanc Biopharma, Inc. - Common Stock is publicly traded.

What exchange does Propanc Biopharma, Inc. - Common Stock trade on?

Propanc Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Propanc Biopharma, Inc. - Common Stock?

The ticker symbol for Propanc Biopharma, Inc. - Common Stock is PPCB on the Nasdaq Stock Market

What is the current price of Propanc Biopharma, Inc. - Common Stock?

The current price of Propanc Biopharma, Inc. - Common Stock is 0.3530

When was Propanc Biopharma, Inc. - Common Stock last traded?

The last trade of Propanc Biopharma, Inc. - Common Stock was at 01/15/26 03:47 PM ET

What is the market capitalization of Propanc Biopharma, Inc. - Common Stock?

The market capitalization of Propanc Biopharma, Inc. - Common Stock is 4.72M

How many shares of Propanc Biopharma, Inc. - Common Stock are outstanding?

Propanc Biopharma, Inc. - Common Stock has 5M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.